Business Wire

Saladax Biomedical, Inc. Acquires Intellectual Property Portfolio for Antipsychotic Drug Tests

Share

Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are prescribed worldwide and places Saladax in a premier position in the antipsychotic drug testing field.

With this IP portfolio, Saladax has developed tests for chemistry analyzers commonly found in hospitals and a point-of-care instrument that can be used where centralized testing is not possible. These tests address a significant unmet clinical need for patients with serious mental illness (SMI) by providing rapid, actionable results to health care professionals (HCP). International and U.S. clinical guidelines have recently been established recommending antipsychotic drug testing. The availability of these tools will greatly enhance the ability of health care professionals to better manage their patients in real time.

SMI is a significant public health concern. The estimated economic impact of SMI worldwide is more than $2.5 trillion each year with the number of people that SMI affects growing rapidly. In the U.S. current data shows that more than 13 million adults in the U.S. experienced SMI in the past year. That is more than 3% of the adult population.1

Saladax is well positioned as the leading diagnostic company in the field of antipsychotic drug testing with a full panel of antipsychotic tests already on the market and a solid pipeline of new products.

“This is a very exciting time for Saladax and the field of therapeutic drug monitoring (TDM).” stated Sal Salamone, Founder and CEO of Saladax. “The availability of antipsychotic testing is arguably the most significant step in the field of TDM since the launch of the Abbott Diagnostics TDx platform back in the 1980’s.”

About Saladax Biomedical, Inc.

Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians in monitoring and optimizing patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com.

  1. Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
  2. Bessonova L, Ogden K, The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature review 2011. doi: 10.2147/CEOR.S259338

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Saladax Biomedical, Inc.
Salvatore Salamone
ssalamone@saladax.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Grovara Partners with Dubai Global Connect, Establishes Middle East HQ and Showroom19.5.2022 13:00:00 CEST | Press release

Grovara, the easy global wholesale experience, announces it has signed a lease agreement and become formally incorporated to do business in Dubai as part of a partnership with Dubai Global Connect (DGC), a permanent wholesale market that facilitates business between international buyers and sellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005017/en/ Grovara and Dubai Global Connect cemented their partnership on April 26, 2022 at DGC's new Visitor Centre in Dubai. Standing, from left are Grovara Sales Director Eugenia Schlitter, Grovara Executive Chairman David Pottruck, Grovara Chief Innovation Officer/Co-founder Peter Groverman, Dubai Global Connect Food Business Development Lead Badreddine Soukarie, and Grovara VP of Global Supply Chain Juliana Rogenski; Seated, from left are Dubai Global Connect Head of Business Development Paul Boots and Grovara CEO/Co-founder Abu Kamara. (Photo: Business Wire) The partnersh

Zilliant Launches Quick Start Program to Speed Time to Value and First Quick Start Package, Transforming How Companies Manage Pricing in Response to Inflation19.5.2022 13:00:00 CEST | Press release

Zilliant, the industry leader in intelligent end-to-end pricing solutions and sales guidance software, today announced its Zilliant Quick Start Program, which enables significantly faster deployment times for its software and faster time-to-value for customers. The first Quick Start package of this transformative program is Zilliant Quick Start for Global and Country Price Lists, which is available beginning today. In the past, deploying price optimization and management software may have seemed time intensive or difficult to implement. As a direct result, pricing and commercial teams rely on spreadsheets to manage pricing, sales operations and commercial functions, a method that is insufficient to respond to today’s volatile market conditions. The Zilliant Quick Start program flips this paradigm, offering packaged solutions to address specific pricing and sales challenges, each of which can be up and running within the span of three to eight weeks, work seamlessly with each other on t

Eaton Introduces DC-DC Converters for 48-Volt Commercial Vehicle Architectures19.5.2022 12:30:00 CEST | Press release

Power management company Eaton today introduced a family of 48-volt DC-DC converters for diesel-powered commercial vehicles that can be used to power accessories such as antilock brakes and lighting. Unlike competitive offerings, Eaton’s DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005093/en/ Eaton’s family of 48-volt DC-DC converters can be used to power accessories such as antilock brakes and lighting and are operational in ambient temperatures up to 85 degrees Celsius. (Graphic: Business Wire) “DC-DC converters are an essential part of our eMobility product portfolio and are used in a variety of vehicle applications,” said Ben Karrer, director, Technology Development, Eaton’s eMobility business. “Many commercial vehicle manufacturers are transitioning to 48-volt architectures, so having the ability to

UZ Brussel First to Treat Breast Cancer Patients with New Brainlab Deep Inspiration Breath Hold with Instant X-Ray Confirmation19.5.2022 12:01:00 CEST | Press release

Brainlab announced today that clinicians at UZ Brussel are the first to treat patients with the company’s new Deep Inspiration Breath Hold (DIBH)* technology designed to streamline image guided and surface guided radiation therapy (IGRT and SGRT) and deliver the highest quality of care for breast cancer patients. UZ Brussel is a university hospital at the Vrije Universiteit Brussel with 721 hospital beds and almost 4,000 employees. UZ Brussel successfully validated the technology and presented research at the Novalis Circle Symposium at ESTRO on May 8, 2022. The research demonstrates that Brainlab ExacTrac Dynamic® DIBH streamlines the process and increases positioning confidence through “on-the-fly” X-Ray confirmation. Internal anatomy verification at the breath hold level may increase confidence in dose sparing of critical structures like the heart. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005985/en/ CE-marked

Booba and Silent Seeds Announce the Launch of a New Strain of Cannabis (THC), the B-45!19.5.2022 11:35:00 CEST | Press release

Alexandre Lacarré, the co-founder of the Silent Seeds seed bank (formerly Dinafem) and the famous French rapper Booba, have announced a unique cooperation to create B-45, a seed specially designed for the artist. A first in Europe! This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005106/en/ (Photo: Silent Seeds) With 20 years of experience and R&D, Silent Seeds was Booba's partner of choice for the creation and distribution of his own strain of cannabis, entirely tailor-made for an exceptional result. Friday 20 May 2022 will mark the launch of B-45, an Indica-dominant hybrid resulting from crossing (Florida OG x Pre'98 Bubba Kush) x Orange Punch #66. This strain has a record THC content of more than 30%. "If you want to visit Jamaica, you just have to taste my weed". -Booba "From our first meeting, Booba knew exactly what he wanted. We soon came to the conclusion that the cannabis plant held no secrets for him. We would